NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 17 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
Silvercorp Metals Inc. (NYSE-A/TSX: SVM) Added to S&P/TSX Composite Index After a Year of Growth
Disseminated on behalf of Silvercorp Metals Inc. (NYSE-A/TSX: SVM) and includes paid advertisement. Analysts remain…
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Expands LIFE Investment Opportunity Amid Ramp-up to Abitibi Belt Production
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) and may include…
-
QualityStocksNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Establishes Snapt Beverages as Vertically Integrated Manufacturing and Brand Platform
Golden Triangle Ventures (OTC: GTVH) (“GTV”) announced the establishment of Snapt Beverages as its manufacturing and…